This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stump, D. C. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Stump, D. C. Articles by Collen, D.

Circulation, Vol 80, 1222-1230, Copyright © 1989 by American Heart Association

ARTICLES

Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group

DC Stump, RM Califf, EJ Topol, K Sigmon, D Thornton, R Masek, L Anderson and D Collen
Department of Medicine, University of Vermont, College of Medicine, Burlington.

Coagulation analysis was performed on blood samples from 386 patients with acute myocardial infarction drawn before, during, and after a continuous intravenous infusion of 150 mg recombinant tissue-type plasminogen activator (rt-PA) (Activase). Plasma rt-PA rose to peak levels of 2.1 +/- 3.1 micrograms/ml (mean +/- SD). Fibrinogen levels measured by coagulation rate and by sulfite precipitation decreased from baseline levels of 3.0 +/- 0.9 and 3.2 +/- 1.0 g/l, respectively, to nadir levels of 1.4 +/- 0.75 and 1.8 +/- 0.92 g/l, respectively, and were associated with peak levels in serum of fibrinogen-degradation products (FDP) of 230 +/- 470 micrograms/ml. Forty percent of patients experienced a nadir functional-fibrinogen level of less than 1.0 g/l, whereas 20% fell below 0.5 g/l. Nadir fibrinogen levels did not correlate with patency of the infarct-related coronary artery at 90 minutes or with risk of coronary vessel reocclusion within 7-10 days. However, the risk of coronary artery reocclusion was inversely related to the baseline functional fibrinogen level (p = 0.0008), with the magnitude of its drop to nadir level (p = 0.0003) as well as to peak levels of FDP (p = 0.038). Quantitative blood loss correlated with all markers for systemic fibrinogenolysis including nadir fibrinogen level (r = -0.20, p = 0.0011), percent decrease of fibrinogen (r = 0.22, p = 0.001), and peak FDP levels (r = 0.14, p = 0.020). Both patients who experienced intracranial hemorrhage presented with high baseline fibrinogen levels and experienced extensive degradation of coagulable fibrinogen. Overall, patients at greatest risk of systemic fibrinogenolysis tended to be relatively older women with lower body weight.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. Stewart, M. Kong, V. Novokhatny, G. Jesmok, and V. J. Marder Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage Blood, April 15, 2003; 101(8): 3002 - 3007. [Abstract] [Full Text] [PDF]

				Y. Kotsuka, O. Tanaka, S. Takamoto, and A. Furuse Intravalvular implantation technique for aortic valve replacement in aortitis syndrome Ann. Thorac. Surg., January 1, 1999; 67(1): 89 - 92. [Abstract] [Full Text] [PDF]

				J. Meehan Carr, E. G. Bovill, R. P. Tracy, M. Mankowski, K. G. Mann, and J. McDonagh Changes in Fibrinogen After rt-PA Administration Clinical and Applied Thrombosis/Hemostasis, January 1, 1996; 2(1): 43 - 50. [Abstract] [PDF]

				C. R. Benedict, C. J. Refino, B. A. Keyt, R. Pakala, N. F. Paoni, G. R. Thomas, and W. F. Bennett New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA Circulation, November 15, 1995; 92(10): 3032 - 3040. [Abstract] [Full Text]

				S. Vanderschueren, L. Barrios, P. Kerdsinchai, P. Van den Heuvel, L. Hermans, M. Vrolix, F. De Man, E. Benit, L. Muyldermans, D. Collen, et al. A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction Circulation, October 15, 1995; 92(8): 2044 - 2049. [Abstract] [Full Text]

				F. Leya, J. Fareed, and J. Walenga Acute Myocardial Infarction: Diagnosis and Management Clinical and Applied Thrombosis/Hemostasis, March 1, 1995; 1(2): 160 - 165. [Abstract] [PDF]

				J. Strony, A. Song, L. Rusterholtz, and B. Adelman Aurintricarboxylic Acid Prevents Acute Rethrombosis in a Canine Model of Arterial Thrombosis Arterioscler Thromb Vasc Biol, March 1, 1995; 15(3): 359 - 366. [Abstract] [Full Text]

				H. V. Anderson and J. T. Willerson Thrombolysis in Acute Myocardial Infarction N. Engl. J. Med., September 2, 1993; 329(10): 703 - 709. [Full Text]

				S. J. Gardell The Search for the Ideal Thrombolytic Agent: Maximize the Benefit and Minimize the Risk Toxicol Pathol, January 1, 1993; 21(2): 190 - 198. [Abstract] [PDF]

				E. G. Bovill, M. L. Terrin, D. C. Stump, A. D. Berke, M. Frederick, D. Collen, F. Feit, J. M. Gore, L. D. Hillis, C. T. Lambrew, et al. Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial Ann Intern Med, August 15, 1991; 115(4): 256 - 265. [Abstract] [PDF]